Literature DB >> 23864319

[Diabetes and osteoporosis: pathophysiological interactions and clinical importance for geriatric patients].

M Lechleitner1, K Pils, R Roller-Wirnsberger, E Beubler, R Gasser, P Mrak, F Hoppichler, P Pietschmann.   

Abstract

Osteoporosis is an age-associated disease, resulting in impaired bone quality and increased risk for bone fractures. Patients with type 2 diabetes mellitus have--despite a normal or even increased bone mineral density--an increased risk for fractures, which is related to an imbalance between osteoblastic bone formation and osteoclastic resorption. Complex pathophysiological mechanisms associated with insulin resistance and hyperglycemia are involved in the deleterious effects on osteoblast function and bone formation. The quality and regimen of antidiabetic therapy are discussed as modulators of bone metabolism. Of great clinical importance is an assessment of the fall risk especially for diabetic patients, because late complications, such as neuropathy, but also side effects of medication can result in a significantly increased risk for falls. Lifestyle intervention is of advantage with respect to diabetes and osteoporosis prevention and therapy. Vitamin D supplementation results in favorable effects with a reduced risk for falls and also improvements of insulin sensitivity. According to published data, the safety and efficacy of specific medication for the treatment of osteoporosis (bisphosphonates, denosumab, selective estrogen receptor modulators) reveal no difference between patients with and without diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23864319     DOI: 10.1007/s00391-013-0518-4

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  80 in total

Review 1.  Cell biology of osteoimmunology.

Authors:  Reinhard Gruber
Journal:  Wien Med Wochenschr       Date:  2010-08-16

2.  Potential pitfalls of disease-specific guidelines for patients with multiple conditions.

Authors:  Mary E Tinetti; Sidney T Bogardus; Joseph V Agostini
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

3.  RETRACTED: Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  Diabetes Res Clin Pract       Date:  2011-04-27       Impact factor: 5.602

Review 4.  Physical exercise for the prevention and treatment of type 2 diabetes.

Authors:  C Sanz; J-F Gautier; H Hanaire
Journal:  Diabetes Metab       Date:  2010-08-02       Impact factor: 6.041

Review 5.  Type 2 diabetes and bone.

Authors:  William D Leslie; Mishaela R Rubin; Ann V Schwartz; John A Kanis
Journal:  J Bone Miner Res       Date:  2012-09-28       Impact factor: 6.741

6.  Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.

Authors:  Mathijs C Bunck; Marieke Poelma; E Marelise Eekhoff; Anja Schweizer; Robert J Heine; Giel Nijpels; James E Foley; Michaela Diamant
Journal:  J Diabetes       Date:  2012-06       Impact factor: 4.006

7.  Sex differences in the risk of frailty for mortality independent of disability and chronic diseases.

Authors:  Martine T E Puts; Paul Lips; Dorly J H Deeg
Journal:  J Am Geriatr Soc       Date:  2005-01       Impact factor: 5.562

8.  Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women.

Authors:  K K Nicodemus; A R Folsom
Journal:  Diabetes Care       Date:  2001-07       Impact factor: 19.112

9.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

Review 10.  Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

Authors:  Michael McClung; Steven T Harris; Paul D Miller; Douglas C Bauer; K Shawn Davison; Larry Dian; David A Hanley; David L Kendler; Chui Kin Yuen; E Michael Lewiecki
Journal:  Am J Med       Date:  2012-11-20       Impact factor: 4.965

View more
  2 in total

Review 1.  Obesity: Friend or foe for osteoporosis.

Authors:  Sudhaa Sharma; Vishal R Tandon; Shagun Mahajan; Vivek Mahajan; Annil Mahajan
Journal:  J Midlife Health       Date:  2014-01

2.  Effects and Mechanism of Zishen Jiangtang Pill on Diabetic Osteoporosis Rats Based on Proteomic Analysis.

Authors:  Shufang Chu; Deliang Liu; Hengxia Zhao; Mumin Shao; Xuemei Liu; Xin Qu; Zengying Li; Jinhua Li; Huilin Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-24       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.